Priority review NDA puts oral SERD giredestrant on PDUFA track for ER-positive, HER2-negative breast cancer, cutting recurrence risk in lidERA.

In an interview with Pharmacy Times, Caitlin Jones, PhD, discusses why high-risk, low-benefit treatments for chronic low back pain require greater scrutiny.

Interim data—briefly held back from the CDC’s own weekly report—show the reformulated shot added meaningful protection even among adults with substantial existing immunity.

Timothy Clifford, PharmD, outlines how quality-of-life impact, comorbid conditions, and prior therapy failures guide biologic selection for CRSwNP.

In an interview with Pharmacy Times, Alison Newman, MPH, program operations specialist with the Center for Community-Engaged Drug Education, Epidemiology, and Research at the Addictions, Drug & Alcohol Institute at the University of Washington, discusses the significance of OTC naloxone availability and the barriers that remain despite the introduction of additional products.

Aderonke Adeboye, PharmD, discusses the clinical red flags that signal a patient with CSU needs advanced therapy and how specialty pharmacists guide treatment selection and support long-term adherence for biologics and emerging oral agents.